galvokimig (UCB9741) / UCB - LARVOL DELTA

The IL-13/IL-17 Dual Inhibition Frontier: An Early-Stage Comparative Analysis of Galvokamig Can Targeting TH-17 Cytokines Disrupt the Intrinsic Heterogeneity of Atopic Dermatitis Endotypes (EADV 2026) - No abstract available

Heterogeneity • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13 • IL17A

Galvokimig, a multispecific, antibody-based IL-13, IL-17A and IL-17F inhibitor, modulates lesional transcriptome and circulating biomarkers in atopic dermatitis: findings from a 12-week Phase 2a trial (EADV 2026) - No abstract available

Biomarker • P2a data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13 • IL17A

Galvokimig, a multispecific antibody-based therapeutic, attenuates key immune pathways in atopic dermatitis: transcriptomic insights from a Phase 2a trial (ESDR 2026) - No abstract available

P2a data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

ATMOS: A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: UCB Biopharma SRL | Not yet recruiting ➔ Recruiting

Enrollment open • Bronchiectasis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

SCALA: A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (clinicaltrials.gov) - P2 | N=402 | Not yet recruiting | Sponsor: UCB Biopharma SRL

New P2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

SCALA: A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (clinicaltrials.gov) - P2 | N=402 | Recruiting | Sponsor: UCB Biopharma SRL | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

ATMOS: A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: UCB Biopharma SRL

New P2 trial • Bronchiectasis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis (clinicaltrials.gov) - P2 | N=160 | Recruiting | Sponsor: UCB Biopharma SRL | N=92 ➔ 160

Enrollment change • Trial initiation date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis (clinicaltrials.gov) - P2 | N=92 | Recruiting | Sponsor: UCB Biopharma SRL | N=46 ➔ 92

Enrollment change • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

ATD002: A study to learn if galvokimig is safe and works in adults with moderate to severe atopic dermatitis (clinicaltrialsregister.eu) - P1/2 | N=46 | Not yet recruiting | Sponsor: UCB Biopharma

New P1/2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

BE BOLD is a head-to-head post-approval Phase 4 study, comparing bimekizumab, an IL-17A and IL-17F inhibitor, with risankizumab, an IL-23 inhibitor, in the treatment of adults with active psoriatic arthritis (PsA). (UCB Press Release) - "BE BOLD is the first head-to-head study in PsA evaluating the superiority of an IL-17A and IL-17F inhibitor to an IL-23 inhibitor. Thanks to faster recruitment than anticipated, first headline results are now expected in H1 2026."

P4 data • Trial status • Psoriatic Arthritis

UCB has started a Phase 2b program with galvokimig in participants with atopic dermatitis to investigate the optimal dose and dosing regime using a subcutaneous application, with blinded dosing until week 52. First headline results are expected in 2028. (UCB Press Release)

P2b data • Atopic Dermatitis

UCB will explore the potential of galvokimig in respiratory diseases: two respiratory indications, Chronic Obstructive Pulmonary Disease (COPD) and Non-Cystic Fibrosis Bronchiectasis (NCFB), with respective proof of concept studies (phase 2a) starting later in 2026. (UCB Press Release)

New P2a trial • Chronic Obstructive Pulmonary Disease • Non‐Cystic Fibrosis Bronchiectasis

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis (clinicaltrials.gov) - P2 | N=160 | Recruiting | Sponsor: UCB Biopharma SRL | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: UCB Biopharma SRL

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A first-in-patient 18-week study of galvokimig, a multispecific antibody-based therapeutic targeting interleukin (IL)-13, IL-17A, and IL-17F in participants with moderate-to-severe atopic dermatitis (AD) (ISDS 2025) - P1/2 | "Galvokimig demonstrated a clinically meaningful and rapid improvement in efficacy measures and an acceptable benefit–risk profile in participants with AD. Phase 2/3 studies will further determine the benefit–risk profile of subcutaneous galvokimig in AD."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Hematological Disorders • Immunology • Infectious Disease • Inflammation • IL13 • IL17A

Galvokimig, a multispecific antibody-based therapeutic, for the treatment of inflammatory skin diseases associated with both type 2 and type 3 inflammation (ISDS 2025) - "Treatment with galvokimig inhibited cytokines and signaling pathways associated with atopic dermatitis pathobiology. Galvokimig recently completed a Phase 1/2a clinical trial."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL13 • IL17A • IL4 • IL6

UCB stock price target raised to EUR285 by Deutsche Bank on galvokimig data (Investing.com) - "Deutsche Bank raised its price target on UCB SA...to EUR285.00 from EUR250.00 on Monday, while maintaining a Buy rating on the Belgian pharmaceutical company....The price target increase follows Deutsche Bank’s analysis of Phase 2a trial data for galvokimig, which were presented at the European Academy of Dermatology and Venereology (EADV) conference two weeks ago and discussed during a UCB investor call last week."

Stock price • Atopic Dermatitis

A first-in-patient 18-week study of galvokimig, a multispecific antibody–based therapeutic targeting interleukin (IL)-13, IL-17A, and IL-17F in participants with moderate-to-severe atopic dermatitis (AD) (EADV 2025) - P1/2 | "This first-in-patient study met its primary endpoints, with galvokimig demonstrating a clinically meaningful and rapid improvement in efficacy measures, and safety outcomes associated with an acceptable benefit–risk profile. Phase 2/3 studies will further determine the benefit–risk profile of galvokimig administered subcutaneously in participants with AD."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • IL13 • IL17A

UCB announces successful first-in-patient trial for galvokimig in moderate-to-severe atopic dermatitis at EADV (UCB Press Release) - "In the Phase 2a trial, patients (n=47) received galvokimig (n=33) or placebo (n=14). At Week 12, a median of 64.9% of patients achieved EASI75 with galvokimig versus 12.3% with placebo. Also at Week 12, a median of 46.6% of patients achieved EASI90 with galvokimig versus 3.5% with placebo....After 18 weeks, the most common treatment-emergent adverse events (TEAEs) with galvokimig were rhinitis, nasopharyngitis, headache, dizziness and oropharyngeal pain."

P2a data • Atopic Dermatitis

Galvokimig, a multispecific antibody-based therapeutic, for the treatment of inflammatory skin diseases associated with both type 2 and type 3 inflammation (ESDR 2025) - "Funding: UCB. Medical writing and editorial assistance: HCG."

Atopic Dermatitis • Dermatitis • Dermatology • Inflammation • IL13 • IL17A • IL4 • IL6

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth (PRNewswire) - "UCB9741/ galvokimig...The phase 2a study in moderate-to-severe atopic dermatitis - a type of eczema, which is the most common inflammatory skin disease - showed positive and convincing proof-of-concept data – to be presented at an upcoming scientific meeting in 2025...UCB1381/ donzakimig...Recruitment for the Phase 2a study in atopic dermatitis (AtD) is progressing slower than anticipated, leading to an updated timeline with results now expected in the second half of 2025...The phase 3 study to evaluate the efficacy and safety of bimekizumab in Chinese study participants with moderate to severe plaque psoriasis (PSO) reported positive results...Submission to the Chinese regulatory authorities is planned for H2 2025."

China filing • P2a data • Atopic Dermatitis • Psoriasis

A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: UCB Biopharma SRL | Active, not recruiting ➔ Completed

Trial completion

A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: UCB Biopharma SRL | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis (clinicaltrials.gov) - P1/2 | N=107 | Completed | Sponsor: UCB Biopharma SRL | Phase classification: P1 ➔ P1/2

Phase classification • Atopic Dermatitis • Dermatitis • Dermatology • Immunology